To address this issue, we developed an in vitro approach to study the priming of SARS-CoV-2-specific CD8+ T-cell responses from naive cells in healthy unexposed individuals of different age groups, without the influence of the infection or comorbidities in infected patients. The gene discussed is CD8A; the disease is infection.